



UCB  
News

## UCB files a public exchange offer on its bonds maturing in November 2014

**BRUSSELS, September 3rd, 2013 (CET) – regulated information**

On September 2nd 2013, UCB SA (NYSE Euronext UCB) has filed an exchange offer prospectus with the Belgian Financial Services and Markets Authority (“**FSMA**”) in connection to an unconditional public exchange offer (“**Exchange Offer**”) on maximum 250,000 out of the 750,000 fixed rate bonds (ISIN Code: BE6000431112) maturing November 27th 2014 and having a gross coupon of 5.75% (“**Existing Bonds**”).

Under the proposed Exchange Offer, the existing bondholders will have the opportunity to exchange their Existing Bonds against newly issued bonds with a gross coupon of 5.125% maturing on October 2nd 2023, in an exchange ratio of 1 to 1.

Holders of Existing Bonds that are exchanged in the proposed Exchange Offer will receive New Bonds with a nominal value of EUR 1,000 and a yield of 5.125% per annum (gross), corresponding to the addition of three foregoing elements: (i) 4.461% (corresponding to the gross yield for a new 10-year bond issued at par by UCB, as evaluated by the Offeror) + (ii) 0.564% (the report and spreading of the unrealized gain of the Existing Bonds over the ten years of the New Bond) + (iii) 0.1% (tender premium). The net actuarial yield for natural persons domiciled in Belgium (taking into account the 25% withholding tax) for the New Bonds amounts to 3.421% (calculated at par on the basis of items (i) and (iii) above only).

The accrued interests since November 27th 2012 on the Existing Bonds delivered to the proposed Exchange Offer will be paid on October 2nd 2013.

The prospectus relating to the Exchange Offer remains subject to approval by the FSMA.

In this operation, BNP Paribas Fortis, ING Bank and KBC Bank act as dealer managers and joint bookrunners. ING Bank has also acted as global coordinator.

The newly issued bonds will be offered to retail investors in Belgium and qualified investors in the European Union. They will be offered to non-US persons outside the US pursuant to regulation S under the US Securities Act 1933, as amended.

By this voluntary exchange transaction, UCB wishes to extend part of its existing bond financing. For the existing bondholder, the opportunity is offered to take advantage of a slight premium over the existing market price in connection to fixed rate bonds (ISIN Code: BE6000431112) maturing 27 November 2014.



Inspired by patients.  
Driven by science.

**For further information**

Antje Witte, Investor Relations UCB  
T +32.2.559.9414, [antje.witte@ucb.com](mailto:antje.witte@ucb.com)

**About UCB**

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).

**Forward looking statements**

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

**Disclaimer**

**THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE THE KINGDOM OF BELGIUM, AND IN PARTICULAR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW**

THIS ANNOUNCEMENT IS FOR GENERAL INFORMATION ONLY AND DOES NOT FORM PART OF ANY OFFER TO SELL OR EXCHANGE, OR THE SOLICITATION OF ANY OFFER TO BUY OR EXCHANGE, SECURITIES. THE DISTRIBUTION OF THIS ANNOUNCEMENT AND THE OFFER AND SALE OR EXCHANGE OF THE SECURITIES DESCRIBED IN THIS ANNOUNCEMENT MAY BE RESTRICTED BY LAW IN CERTAIN JURISDICTIONS. EACH PERSON READING THIS ANNOUNCEMENT SHOULD INFORM HIMSELF OF AND OBSERVE ANY SUCH RESTRICTIONS.

THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES IN THE UNITED STATES OR ANY OTHER JURISDICTION. THE BONDS MAY NOT BE OFFERED NOR SOLD OR EXCHANGED IN THE UNITED STATES ABSENT REGISTRATION OR AN EXEMPTION FROM REGISTRATION UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE "**SECURITIES ACT**"). UCB DOES NOT INTEND TO REGISTER ANY PORTION OF THE PLANNED OFFER IN THE UNITED STATES OR TO CONDUCT AN OFFERING OF SECURITIES IN THE UNITED STATES. THE OFFERING IS BEING CONDUCTED OUTSIDE THE UNITED STATES IN ACCORDANCE WITH REGULATIONS UNDER THE SECURITIES ACT.

THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND NOT A PROSPECTUS WITHIN THE MEANING OF THE LAW OF 1 APRIL 2007 ON PUBLIC TAKEOVER BIDS.

THE DEFINITIVE TERMS OF THE TRANSACTIONS DESCRIBED HEREIN ARE DESCRIBED IN THE PROSPECTUS PREPARED IN RELATION TO BE EXCHANGE OFFER (THE "**PROSPECTUS**"). INVESTORS SHOULD NOT

PARTICIPATE IN THE EXCHANGE REFERRED TO HEREIN EXCEPT ON THE BASIS OF INFORMATION CONTAINED IN THE FINAL FORM OF THE PROSPECTUS.

OUTSIDE THE KINGDOM OF BELGIUM, THIS ANNOUNCEMENT IS ONLY DIRECTED AT QUALIFIED PERSONS AND ANY INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS ONLY AVAILABLE TO QUALIFIED PERSONS OR WILL BE ENGAGED IN ONLY BY QUALIFIED PERSONS. SOLICITATIONS OUTSIDE THE KINGDOM OF BELGIUM RECEIVING FROM THIS ANNOUNCEMENT WILL BE RESPONDED TO IF THE PERSON CONCERNED IS A QUALIFIED PERSON. OTHER PERSONS SHOULD NOT RELY OR ACT UPON THIS ANNOUNCEMENT OR ANY OF THIS CONTENTS.

ANY EXCHANGE OF BONDS OF THE COMPANY PURSUANT TO THE OFFERING SHOULD ONLY BE MADE ON THE BASIS OF THE INFORMATION CONTAINED IN THE PROSPECTUS TO BE ISSUED BY THE ISSUER IN DUE COURSE IN CONNECTION WITH THE OFFERING.